<DOC>
	<DOCNO>NCT02406612</DOCNO>
	<brief_summary>The study design prospectively collect data confirm safety effectiveness X-Seal 6F Vascular Closure System reduce time hemostasis time ambulation patient undergone diagnostic interventional catheterization procedure use 6F sheath compare standard compression technique use data literature survey .</brief_summary>
	<brief_title>X-Seal EU Post-Market Clinical Follow-Up Protocol</brief_title>
	<detailed_description />
	<criteria>Candidate nonemergent diagnostic interventional cardiac catheterization via femoral sheath ≤6F . Age ≥18 year . Understand sign study specific write informed consent form . In investigator 's opinion , patient suitable XSeal vascular closure device , conventional hemostasis technique participation investigational trial . Eligible sheath removal catheterization lab . Patients know pregnant lactating . Patients immunocompromised . Prior target artery closure vascular closure device closure manual compression win 30 day prior procedure . Patients significant anemia ( hemoglobin &lt; 10 g/DL , Hct &lt; 30 ) . Patients morbidly obese cachectic ( BMI &gt; 40 &lt; 20 kg/m2 ) . Patients Systolic Blood Pressure &gt; 180 mmHg , unless Systolic Pressure lower pharmacological agent prior closure Patients currently participate another clinical trial investigational drug device conclude followup period . Patients baseline INR &gt; 1.5 ( e.g . coumadin therapy ) . Patients know bleed disorder include thrombocytopenia ( platelet count &lt; 100,000 cells/UL ) , thrombasthenia , hemophilia , von Willebrand 's disease . Patients small femoral artery ( &lt; 4 mm ) , femoral artery stenosis result vessel diameter &lt; 4 mm , patient severe peripheral vascular disease . Patients puncture site believe profunda femoris , superficial femoral artery , bifurcation artery . Common femoral artery fluoroscopically visible calcium . Femoral artery suspect experienced back wall puncture underwent &gt; one ( 1 ) arterial puncture catheterization procedure . Patients complication ( ) femoral artery access site presheath removal include hematoma , pseudoaneurysm , arteriovenous fistula . Patients continue heparin anticoagulant/antiplatelet therapy plan ( exception Glycoprotein IIb/IIIa receptor blocker ) follow completion catheterization procedure . Patients whose ACT &gt; 300 second prior removal guide catheter . Patients adhere complete investigational protocol reason include limited geographical residence life threaten disease . Prior femoral vascular surgery vascular graft region access site . Patient unable ambulate baseline . Acute STelevation MI within 48 hour prior procedure . Active systemic cutaneous infection inflammation Patients unilateral bilateral low extremity amputation Patients renal insufficiency ( serum creatinine &gt; 2.5 mg/dl ) Patients marked tortuosity femoral iliac artery Patients bacterial contamination procedure sheath surround tissue may occur may result infection Patients puncture site locate inferior border epigastric artery ( IEA ) and/or inguinal ligament base upon bony landmark , since puncture site may result retroperitoneal hematoma/bleed . Perform femoral angiogram verify location puncture site Patients know allergy beef product , collagen and/or collagen product , polyglycolic polylactic acid polymer Patients know allergy stainless steel nickel . See MRI information IFU . Patients undergoing therapeutic thrombolysis Patients puncture vascular graft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vascular Closure Device</keyword>
	<keyword>Femoral Artery Closure</keyword>
</DOC>